Alumis Inc. (ALMS)

Alumis completed patient enrollment in its global LUMUS Phase 2b trial of ESK-001 for systemic lupus erythematosus (SLE), with topline data expected in the third quarter of 2026. The company reported its Third Quarter 2025 financial results. Alumis announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib in patients with moderate-to-severe plaque psoriasis, leading to a significant surge in the stock price. Alumis announced a proposed underwritten public offering of $175.0 million of its common stock and later announced the pricing of its upsized public offering of common stock. Insider buying activity was reported, with Foresite Labs, Llc purchasing 411,764 shares. Alumis announced the closing of its upsized public offering and the full exercise of the underwriters' option to purchase additional shares. Several analysts increased their price targets for Alumis, Inc. following the positive Phase 3 data.

Alumis, Inc.'s products and services are not typically subject to demand seasonality. Demand for its investigational therapies, once approved, would primarily be driven by disease prevalence, treatment efficacy, physician adoption, and market access, rather than seasonal fluctuations.

Alumis, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative medicines for autoimmune disorders, aiming to replace broad immunosuppression with targeted therapies. Envudeucitinib is being developed for the treatment of moderate-to-severe plaque psoriasis and systemic lupus erythematosus (SLE). A-005 is intended for neuroinflammatory and neurodegenerative diseases. The Interferon Regulatory Factor 5 (IRF5) program is focused on addressing immune dysfunction. Lonigutamab is in preclinical and early clinical development for thyroid eye disease.

Alumis, Inc. is headquartered in South San Francisco, California, United States. Its clinical trials are global.

Alumis, Inc.'s brand reputation has been significantly bolstered by positive clinical trial results, particularly the Phase 3 results for envudeucitinib in plaque psoriasis, generating substantial investor enthusiasm and positive analyst sentiment. This success positions Alumis favorably within the healthcare and biotechnology sectors.

Alumis, Inc. has a significant institutional ownership, accounting for 74.71% of its stock, while insiders hold 25.12%, and retail investors hold 0.17%. Major institutional and individual owners include Ayurmaya Capital Management Company LP, Foresite Capital Management V LLC, Samsara BioCapital, LLC, venBio Partners LLC, Foresite Capital Management VI LLC, BlackRock, Inc., Vanguard Group Inc., Trium Capital LLP, and Nextech Invest, Ltd.